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PHM4
COST-EFFECTIVENESS OF TRANSFUSING BLOOD PLATELETS
PREPARED WITH PATHOGEN INACTIVATION TREATMENT IN
CHINA
Staginnus U1, Russell S2
1Premor Associates, New York, NY, USA; 2Premor Associates, Madrid,
Spain
OBJECTIVE: Viral transmission of current (e.g., HIV) infectious
blood-borne pathogens via platelet transfusion is high in China,
and emerging pathogens (e.g., SARS) continue to threaten the
blood supply despite recent advances in blood-banking proce-
dures and security. The INTERCEPT Blood System (IBS) for
platelets has been developed to further reduce pathogen trans-
mission risks during platelet transfusions. The objective of this
study was to assess the cost-effectiveness of using random-donor
platelets (RDP) processed with IBS in China. METHODS: A 
literature-based decision analysis model was used to assess the
cost-effectiveness of the IBS in four patient populations that
account for most of the platelet usage in China: 1) a ten-year old
male with acute lymphocytic leukaemia (ALL); 2) a 50-year old
male with non-Hodgkin’s lymphoma (NHL); 3) a 60-year 
old male undergoing heart bypass surgery (CABG); and 4) a 
70-year old female undergoing a hip arthroplasty. Pathogen
exposure included HIV, HCV, HBV and bacterial contamination.
The model compared projected quality-adjusted life-year saved
(QALY) and costs for patients receiving untreated vs. treated
platelets. RESULTS: The incremental cost per QALY gained by
using RDP + IBS vs. RDP ranged in the most conservative sce-
nario from Yuan321,000–Yuan4,665,000. Sensitivity analysis
including transmission rates reported from epidemic regions
improved the cost-effectiveness dramatically ranging from
Yuan38,000–Yuan565,000. The model was most sensitive to the
rate of HIV transmission and the mortality from bacterial infec-
tion. CONCLUSION: IBS for platelets would be a cost-effective
measure to improve blood safety in China. Given the relatively
high risk of HIV and other viral agents in China as compared to
developed countries, and the recent history of emerging and
migrating viruses, pathogen inactivation with IBS may be con-
sidered as a desirable strategy to signiﬁcantly improve the safety
of platelet transfusions.
PHM5
RECOMBINANT HUMAN FACTOR VII USE: AN EVALUATION
OF PATIENT CHARACTERISTICS AND OUTCOMES FROM AN
ELECTRONIC DATABASE OF ACADEMIC HEALTH CENTERS
Magnetti S, Oinonen M, Matuszewski K
University HealthSystem Consortium, Oak Brook, IL, USA
OBJECTIVES: To describe patient characteristics and selected
outcomes related to the inpatient use of recombinant human
factor VII (RHF7) in US academic health centers (AHC).
METHODS: All discharges from the fourth quarter 2001 to
third quarter 2004 were captured from AHCs participating in
the University HealthSystem Consortium’s Clinical Database-
Pharmacy. Descriptive statistics were used to evaluate patient
demographics and coded diagnoses. Other outcomes of interest
included in-hospital mortality, total hospital costs and charges,
and length of stay. RESULTS: A total of 37 AHCs were included
in the analysis, representing 1889 discharges. The mean patient
age was 43 years (SD 23, median 47). Sixty-six percent were
male and 51% were white. Ten DRGs accounted for approxi-
mately 50% of the cases, with the top 3 most frequently cited
being those for tracheostomy (11%), coagulation disorders
(9%), and liver transplant (8%). Of the total 645 unique primary
diagnoses, 13% were related to chronic liver diseases or seque-
lae followed by coagulation factor deﬁciency and defects as the
next most frequently cited reasons for admission (9%). The
mean length of stay was 23 days (SD 30, median 13). The mean
total hospital cost per case was $121,240 (SD $151,047, median
$72,351). The mean total hospital charges per case were
$281,548 (SD $382,151, median $156,048). The in-hospital
mortality rate was 39%. CONCLUSION: RHF7F carries FDA-
approval for marketing (in 1999) in bleeding patients with hemo-
philia A or B who have developed antibody inhibitors to factor
VIII or IX. Given the wide range of DRGs and primary diag-
noses recorded, substantial off-label use appears to be common
medical practice.
PHM6
A HIDDEN EPIDEMIC AMONG ACUTE CARE INPATIENTS:
ECONOMIC AND CLINICAL IMPACTS OF ANEMIA IN
SELECTED CHRONIC DISEASES
Wang PF, Saunders WB, Gaylord B,Vardireddy N
Premier Health Informatics, Charlotte, NC, USA
OBJECTIVES: 1) To understand the prevalence of anemia
among hospital inpatients with selected chronic diseases; and 2)
to evaluate current anemia treatment strategy in acute care hos-
pitals. METHODS: Using Premier’s PerspectiveTM Comparative
database, the largest US hospital database, all inpatients dis-
charged between January, 2003 and December, 2003 with a
primary diagnosis of chronic kidney disease, congestive heart
failure, diabetes, cancer, AIDS, and rheumatoid arthritis were
retrieved. Anemia was identiﬁed using ICD codes (280–285).
Patient demographics, insurance type, institution characteristics,
severity, and anemic treatment patterns were examined. Out-
comes variables included length of stay, total cost, and in-
hospital mortality. RESULTS: Of 300,494 subjects, close to a
quarter (23.5%) were diagnosed with anemia. Prevalence rates
varied by disease from 46.1% (chronic renal insufﬁciency) to
20.2% (diabetes). Only 20.4% anemics received epoetin alfa and
13.7% received iron supplement. Anemic patients were associ-
ated with longer length of stay (4.9 vs. 7.6 days, P < 0.01), higher
total hospitalization cost ($8014 vs. $11,752, P < 0.01) and ele-
vated in-hospital mortality (4.3% vs. 6.1%). CONCLUSIONS:
Anemia is associated with many chronic diseases among acute
care inpatient populations. It is often under-treated with less than
one third of the anemic patients receiving readily available drugs.
When left untreated anemia can be associated with suboptimal
clinical and economic outcomes.
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PHP1
COST EFFECTIVENESS OF INTERVENTIONS TO IMPROVE
ADHERENCE: WHAT IS THE QUALITY OF THE EVIDENCE?
Elliott RA1, Barber N2, Horne R3
1Harvard University, Boston, MA, USA; 2University of London,
London, UK; 3University of Brighton, Brighton, Sussex, UK
OBJECTIVE: To determine whether cost effectiveness evidence
on adherence-enhancing interventions (AEIs) was of sufﬁcient
quality to inform policy decision-making. METHODS: A com-
puterised search of Embase, Medline, Cinahl, Econlit, NHSEED,
Psychlit, ePIC and Cochrane databases from January, 1980 to
April, 2004 was performed. English-language human subject
articles were identiﬁed using an inclusive search strategy. Studies
that appeared to assess the cost effectiveness of medication
adherence-enhancing interventions were included. Methodologic
rigor was assessed using 15 clinical, economic and adherence-
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speciﬁc quality criteria developed by the authors. RESULTS: We
found 45 comparative studies in 43 publications. Asthma (14
studies) and psychiatric illness (12 studies) were most commonly
investigated. In 33 studies, interventions were educational, 20
had multiple components and 23 did not appear to be linked to
proven reasons for non-adherence. No studies assessed manage-
ment of unintentional non-adherence. No study met all quality
criteria. Study quality has not improved with time, as some better
studies are over ten years old. Many studies used inadequate or
unidentiﬁable adherence measures. Critically, many were too
small or not randomised. All studies assumed that patients were
prescribed appropriate therapy for their condition, and no
assessment of treatment quality was made by any study. Report-
ing of adherence and outcome results was often unclear. Cost
data were poorer quality than outcome data, using average or
estimated costs and omitting some cost elements. Nine studies
carried out incremental economic analysis. CONCLUSIONS:
We were not able to make deﬁnitive conclusions about the cost-
effectiveness of medication adherence enhancing interventions
due to the heterogeneity of the studies found and incomplete
reporting of results. Important policy decisions need to be made
about non-adherence, however, they are currently being made in
a vacuum of adequate information. Medication adherence-
enhancing interventions must be based on reasons for non-
adherence and be evaluated using accepted clinical and economic
quality criteria.
PHP2
THE MEDINET-PROJECT—A FEASIBILITY STUDY ON
MEDICATION COMPLIANCE UNDER REAL LIFE CONDITIONS
Sterz R1, Lebmeier M2, Simon U3
1Abbott GmbH & Co. KG, Ludwigshafen, Rhineland-Palati, Germany;
2Shefﬁeld University, Shefﬁeld, UK; 3ES-Q-Lab, Lauf, Bavaria, Germany
OBJECTIVES: To study medication compliance patterns regard-
ing dosing, timing and adherence under real life conditions.
Using a new electronic blister pack system. METHODS: A total
of 37 volunteers from three study centers were each furnished
with an electronic blister holder (“monitor”) and three blister
packs containing 14 placebo capsules each (trial duration: six-
weeks). The monitor measured the disruption of conductive lines
printed on aluminum carrier foil under each capsule and stored
this information (date and time) for evaluation at the end of the
study. Patients had to take out one capsule daily in the morning
over the entire study period. Also patients received a CRF and a
radio-controlled clock such that date and time of the event could
be manually recorded by the patient as well. Data were consid-
ered accurate if the information stored in the monitor and the
corresponding CRF entries were within a time window of ±15
min. RESULTS: All recordings of the electronically stored infor-
mation matched the data documented on the CRFs. This indi-
cates the accurate documentation of the volunteers, as well as
the correct functioning of the monitors. Evaluation of the data,
however, showed a wide intra—as well as interindividual varia-
tion in the time patterns of the volunteers. Three clusters of 
time preference were detected—mornings, noon and late night.
Further, periods of non-compliance (“drug holidays”) as well as
lack of adherence (discontinuation of medication before the end
of the study period of six-weeks) could be documented. CON-
CLUSIONS: The use of the new electronic blister system
improves compliance measurement under real life conditions.
Combining compliance information with other outcome para-
meters will help in better quantifying and optimizing the impact
of patient compliance on clinical and economic outcomes under
real life conditions.
PHP3
IMPACT OF INCREASED COPAYMENTS ON THE SWITCHING
AND DISCONTINUATION RATES FOR NON FORMULARY
MEDICATIONS
Nair KV1,Valuck RJ2
1University of Colorado Health Sciences Center, Denver, CO, USA;
2University of Colorado, Denver, CO, USA
OBJECTIVE: Chronic disease sufferers are particularly affected
by prescription copayment increases as they are faced with deci-
sions to switch to formulary alternatives or pay more to stay on
their current medication. The objective of this study was to eval-
uate the impact of increased prescription copayments as a result
of a change in formulary status on continuation rates of non 
formulary medications in multi-tiered pharmacy beneﬁt plans.
METHODS: Retrospective cohort study of chronic disease
patients from a health plan in the Western U.S. Individuals were
selected who were taking a medication that was being removed
from the health plan’s formulary and thus experienced increases
in their copayments for non formulary medications (n = 1244).
Two time periods were studied: the “pre” period before and the
“post” period after the increase in copayments. Adjusting for
demographics, chronic co-morbidities, medication use, Medicare
+ Choice status and percentage increase in copayment for non
formulary medications, Cox regressions were used to assess 
continuation rates for these medications. RESULTS: A clear 
relationship between increasing copayment differentials and con-
tinuation rates for non formulary medications in the post period
could not be established. In general those who experienced
higher copayment differentials (between 50–100%, 100–200%
and greater than 200%) were more likely to continue their non
formulary medication than those who experienced copayment
increases of 25–50% and less than 25%. CONCLUSIONS: Indi-
viduals confronted with increased copayments often switched
their medications to formulary alternatives. However, a clear
relationship could not be established between increasing copay-
ments and continuation behavior. Further research is needed to
determine if these switching behaviors results in inappropriate
medication behaviors such as complete discontinuation of drug
therapy due to the increased costs.
PHP4
IMPACT OF COST ON MEDICATION COMPLIANCE IN
PATIENTS WITH DIFFERENT LEVELS OF PERCEIVED
BENEFITS
Fuldeore M1, Krueger KP2, Lee K1, Berger BA2, Bertram C1,
Shannon D2, Ekelund R2
1Walgreens Health Initiatives, Deerﬁeld, IL, USA; 2Auburn University,
Auburn, AL, USA
OBJECTIVES: The economics theory of consumer behavior sug-
gests that the impact of cost on product purchasing decisions
depends on the perceived beneﬁts associated with that product.
However, this relationship has been neither demonstrated nor
quantiﬁed for patients taking chronic medications. The objective
of this study was thus to analyze the impact of cost on medica-
tion compliance (reﬁlls) among groups of individuals with dif-
ferent levels of perceived beneﬁts. METHODS: Patients new to
statin therapy were identiﬁed from the prescription database of
a national retail chain. The perceived beneﬁt of the statin med-
ication was measured on a scale of one (low) to seven (high) by
surveying randomly selected new patients. Compliance with the
medication regimen during the ﬁrst 12 months of statin therapy
was measured in terms of the Medication Possession Ratio
(MPR). Information on cost and (MPR) on randomly selected
patients was obtained from the retail chain prescription data-
